,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,11112448,8249,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,410,1,5,,11112448,8249,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
2,411,2,1,,11112448,8249,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
3,444,1,1,,11112448,8249,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
4,445,3,1,,11112448,8249,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
5,446,1,1,,11112448,8249,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
6,447,1,1,,11112448,8249,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
7,448,1,2,,11112448,8249,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
8,450,1,2,,11112448,8249,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
9,451,1,2,,11112448,8249,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
10,526,1,1,,11112448,8249,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
11,530,1,1,,11112448,8249,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
12,584,1,3,,11112448,8249,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
13,585,1,4,,11112448,8249,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
14,587,1,5,,11112448,8249,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
15,588,1,4,,11112448,8249,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
16,589,1,3,,11112448,8249,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
17,590,1,3,,11112448,8249,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
18,591,1,4,,11112448,8249,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
19,592,1,6,,11112448,8249,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
20,593,1,4,,11112448,8249,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
21,594,1,4,,11112448,8249,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
22,595,1,3,,11112448,8249,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
23,596,1,2,,11112448,8249,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
24,597,1,3,,11112448,8249,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
25,603,1,2,,11112448,8249,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
26,605,1,2,,11112448,8249,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
27,607,1,3,,11112448,8249,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
28,662,1,1,,11112448,8249,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
29,875,1,2,,11112448,8249,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
30,880,2,1,,11112448,8249,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
31,880,2,1,,11112448,8249,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
32,881,2,2,,11112448,8249,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
33,883,1,3,,11112448,8249,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
34,884,1,2,,11112448,8249,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
35,885,1,2,,11112448,8249,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
36,886,1,2,,11112448,8249,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
37,886,1,2,,11112448,8249,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
38,887,1,2,,11112448,8249,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
39,889,1,3,,11112448,8249,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
40,891,1,2,,11112448,8249,Inconclusive,40805836.0,1565.0,10.0,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
41,892,1,2,,11112448,8249,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
42,893,1,2,,11112448,8249,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
43,893,1,2,,11112448,8249,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
44,894,2,1,,11112448,8249,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
45,899,1,2,,11112448,8249,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
46,900,1,3,,11112448,8249,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
47,901,1,2,,11112448,8249,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
48,902,1,2,,11112448,8249,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
49,912,1,2,,11112448,8249,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
50,914,1,3,,11112448,8249,Inconclusive,32879895.0,3091.0,6.3096,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
51,915,1,3,,11112448,8249,Inconclusive,32879895.0,3091.0,6.3096,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
52,923,1,2,,11112448,8249,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
53,924,1,2,,11112448,8249,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
54,925,1,2,,11112448,8249,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
55,926,1,2,,11112448,8249,Inconclusive,38016895.0,7253.0,7.9433,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
56,927,1,3,,11112448,8249,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
57,938,1,2,,11112448,8249,Inconclusive,38016895.0,7253.0,7.9433,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
58,995,1,2,,11112448,8249,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
59,1030,2,1,,11112448,8249,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
60,1195,1,2,,48416408,8249,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
61,1332,1,1,,49698378,8249,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
62,1379,1,2,,11112448,8249,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
63,1452,1,1,,11112448,8249,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
64,1454,1,1,,11112448,8249,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
65,1457,1,1,,11112448,8249,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
66,1458,1,1,,11112448,8249,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
67,1467,1,3,,11112448,8249,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
68,1469,1,1,,11112448,8249,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
69,1471,2,1,,11112448,8249,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
70,1476,2,1,,11112448,8249,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
71,1477,1,1,,11112448,8249,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
72,1478,2,1,,11112448,8249,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
73,1479,1,2,,11112448,8249,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
74,1487,1,1,,11112448,8249,Inconclusive,27436948.0,4000.0,0.3981,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
75,1490,2,1,,11112448,8249,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
76,1519,1,3,,11112448,8249,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
77,1688,1,1,,11112448,8249,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
78,1766,1,1,,11112448,8249,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
79,1766,1,1,,11112448,8249,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
80,1768,1,1,,11112448,8249,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
81,1768,1,1,,11112448,8249,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
82,1851,1,2,,11112448,8249,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
83,1851,1,2,1.0,11112448,8249,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
84,1851,1,2,2.0,11112448,8249,Inconclusive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
85,1851,1,2,3.0,11112448,8249,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
86,1851,1,2,4.0,11112448,8249,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
87,1851,1,2,5.0,11112448,8249,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
88,1865,1,1,,11112448,8249,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
89,1948,1,1,,11112448,8249,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
90,2101,1,1,,11112448,8249,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
91,2107,1,1,,11112448,8249,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
92,2112,1,1,,11112448,8249,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
93,2147,1,1,,11112448,8249,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
94,2240,1,1,,85787916,8249,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
95,2241,1,1,,85787916,8249,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
96,2275,1,1,,85787916,8249,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
97,2313,1,1,,85787916,8249,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
98,2316,1,1,,85787916,8249,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,Screening,,
99,2322,1,1,,85787916,8249,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
100,2330,1,1,,85787916,8249,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
101,2451,1,2,,11112448,8249,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
102,2472,1,2,,11112448,8249,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
103,2528,1,2,,11112448,8249,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
104,2546,1,1,,11112448,8249,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
105,2549,1,1,,11112448,8249,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
106,2551,1,1,,11112448,8249,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
107,2662,2,1,,11112448,8249,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
108,54563,3,10,,103426218,8249,Unspecified,117241.0,266684.0,,,Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D1 expressed in Saccharomyces cerevisiae; ND=no data,Other,12502361.0,
109,54564,6,7,,103426218,8249,Active,117242.0,25053.0,45.4,IC50,Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D2 expressed in Saccharomyces cerevisiae,Confirmatory,12502361.0,
110,54565,6,7,,103426218,8249,Unspecified,3915646.0,24303.0,1927.0,IC50,Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D3 expressed in Saccharomyces cerevisiae,Confirmatory,12502361.0,
111,54566,6,7,,103426218,8249,Unspecified,117244.0,,833.0,IC50,Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D4 expressed in Saccharomyces cerevisiae,Confirmatory,12502361.0,
112,54570,6,7,,103426218,8249,Active,84028191.0,1565.0,27.0,IC50,Inhibition of MAMC O-dealkylation mediated by human Cytochrome P450 2D6 expressed in human lymphoblastoid cell line,Confirmatory,12502361.0,
113,75532,3,4,,103426218,8249,Unspecified,,,,,"Hypoglycemic activity was given as differences between the mean changes in blood glucose concentration in control group and the treated group after a dose of 25 mg/kg, ip",Other,4045919.0,
114,77195,3,5,,103426218,8249,Unspecified,,,,,"Evaluated in normal, fasted guinea pig for the percentage reduction in blood glucose level after 5 hr as compared to pretreatment blood glucose values at a dose of 25 mg of free base / kg body weight administered orally",Other,7069714.0,
115,77203,3,5,,103426218,8249,Unspecified,,,,,Percent reduction in blood glucose after perorally administration of compound at 25 mg/kg in in normal fasted guinea pig,Other,7310831.0,
116,126663,3,5,,103426218,8249,Unspecified,,,,,"Evaluated in normal, fasted monkey for the percentage reduction in blood glucose level after 5 hr as compared to pretreatment blood glucose values at a dose of 10 mg of free base / kg body weight administered orally",Other,7069714.0,
117,134583,6,2,,103426218,8249,Unspecified,,,,,Lethal dose after intraperitoneal administration in mouse,Other,7310831.0,
118,134584,6,2,,103426218,8249,Unspecified,,,,,Lethal dose after peroral administration in mouse,Other,7310831.0,
119,172905,4,4,,103426218,8249,Unspecified,,,,,Percent change in blood glucose in normal rats at a hypoglycemic dose of 2.0 mmol/kg. against control,Other,6345781.0,
120,173794,3,3,,103426218,8249,Unspecified,,,,,Compound evaluated for hypoglycemic activity by lowering blood glucose in normal rats by 20% after oral administration; highest dose tested;inactive(less than 10% blood sugar decrease),Other,6864736.0,
121,173795,3,3,,103426218,8249,Unspecified,,,,,Compound evaluated for hypoglycemic activity by lowering blood glucose in streptozotocin-diabetic rats by 20% after oral administration,Other,6864736.0,
122,176493,6,2,,103426218,8249,Unspecified,,,,,Compound evaluated for hypoglycemic activity by lowering blood glucose in normal rats by 50% after oral administration; inactive(less than 10% blood sugar decrease),Other,6864736.0,
123,179727,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level after 0 min following 10 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
124,179728,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level after 0 min following 100 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
125,179729,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level after 0 min following 150 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
126,179736,6,2,,103426218,8249,Unspecified,,,180.0,IC50,In vitro inhibition of glucose oxidation by the compound in isolated rat fat cells,Confirmatory,6345781.0,
127,179876,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level after 0 min following 300 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
128,179877,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level after 0 min following 50 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
129,179878,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level after 30 min following 10 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
130,179879,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level after 30 min following 100 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
131,179880,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level after 30 min following 150 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
132,179882,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level after 30 min following 300 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
133,179883,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level after 30 min following 50 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
134,179884,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level at 10 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
135,179885,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level at 100 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
136,179886,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level at 150 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
137,179888,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level at 300 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
138,179889,8,1,,103426218,8249,Unspecified,,,,,Rise in the blood glucose level at 50 mg/kg oral dose in fasted nondiabetic rats,Other,2769683.0,
139,182468,3,3,,103426218,8249,Unspecified,,,,,"Percent inhibition of glucose rise, following 10 mg/kg oral dose in fasted nondiabetic rats",Other,2769683.0,
140,182469,4,2,,103426218,8249,Unspecified,,,,,"Percent inhibition of glucose rise, following 100 mg/kg oral dose in fasted nondiabetic rats",Other,2769683.0,
141,182470,3,3,,103426218,8249,Unspecified,,,,,"Percent inhibition of glucose rise, following 150 mg/kg oral dose in fasted nondiabetic rats",Other,2769683.0,
142,182472,3,3,,103426218,8249,Unspecified,,,,,"Percent inhibition of glucose rise, following 300 mg/kg oral dose in fasted nondiabetic rats",Other,2769683.0,
143,182473,3,3,,103426218,8249,Unspecified,,,,,"Percent inhibition of glucose rise, following 50 mg/kg oral dose in fasted nondiabetic rats",Other,2769683.0,
144,184645,6,2,,103426218,8249,Unspecified,,,,,Lethal dose required to produce 50% lethality in male and female carworth farms CF-1 strain mice weighing 16-25 g administered intraperitoneally,Other,7069714.0,
145,184646,6,2,,103426218,8249,Unspecified,,,,,Lethal dose required to produce 50% lethality in male and female carworth farms CF-1 strain mice weighing 16-25 g administered orally,Other,7069714.0,
146,188229,3,5,,103426218,8249,Unspecified,,,,,"Evaluated in alloxanized, diabetic rat for the percentage reduction in blood glucose level after 5 hr as compared to pretreatment blood glucose values at a dose of 100 mg of free base / kg body weight administered orally",Other,7069714.0,
147,188241,3,5,,103426218,8249,Unspecified,,,,,"Evaluated in glucose-primed, fasted rat for the percentage reduction in blood glucose level after 2 hr as compared to control groups at a dose of 100 mg of free base / kg body weight administered orally",Other,7069714.0,
148,188896,3,5,,103426218,8249,Unspecified,,,,,Percent reduction in blood glucose after perorally administration of compound at 100 mg/kg in glucose-primed rat,Other,7310831.0,
149,188897,3,5,,103426218,8249,Unspecified,,,,,Percent reduction in blood glucose after perorally administration of compound at 100 mg/kg in in alloxanized rat,Other,7310831.0,
150,188899,3,5,,103426218,8249,Unspecified,,,,,Percent reduction in blood glucose after perorally administration of compound at 120 mg/kg in non-glucose-primed rat,Other,7310831.0,
151,189025,3,5,,103426218,8249,Unspecified,,,,,Percent reduction in blood glucose after perorally administration of compound at 80 mg/kg in non-glucose-primed rat,Other,7310831.0,
152,193166,6,1,,103426218,8249,Unspecified,,,,,In vitro inhibition of glucose oxidation determined in normal rats at a hypoglycemic dose of 2.0 mmol/kg,Other,6345781.0,
153,197698,6,1,,103426218,8249,Unspecified,,,,,In vivo increase of plasma insulin in normal rats at a hypoglycemic dose of 2.0 mmol/kg,Other,6345781.0,
154,204498,8,1,,103426218,8249,Unspecified,,,,,Evaluated for the blood lactate level in 24 hr fasted Sprague-Dawley rats at a dose of 200 mg/kg/day in four divided doses administered intraperitoneally,Other,2329563.0,
155,204499,8,1,,103426218,8249,Unspecified,,,,,Evaluated for the plasma glucose level in 24 hr fasted Sprauge-Dawley rats at a dose of 200 mg/kg/day in four divided doses administered intraperitoneally,Other,2329563.0,
156,352936,3,3,,103426218,8249,Unspecified,,,,,Toxicity in lean normal BALB/c mouse assessed as overt signs of behavioural changes at equimolar dose of 0.5 mmol/kg galegine administered daily through diet for 7 days,Other,19422230.0,
157,352937,3,3,,103426218,8249,Unspecified,,,,,Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.51 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
158,352938,3,3,,103426218,8249,Unspecified,,,,,Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.57 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
159,352939,3,3,,103426218,8249,Unspecified,,,,,Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.70 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
160,352940,3,3,,103426218,8249,Unspecified,,,,,Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.59 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
161,352941,3,3,,103426218,8249,Unspecified,,,,,Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.52 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
162,352948,3,3,,103426218,8249,Unspecified,,,,,Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.40 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
163,352957,3,3,,103426218,8249,Unspecified,,,,,Hypoglycemic activity in lean normal BALB/c mouse assessed as blood glucose level at 0.62 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
164,352962,3,3,,103426218,8249,Unspecified,,,,,Antiobesity activity in lean normal BALB/c mouse assessed as change in average daily food intake at 0.62 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
165,352973,3,3,,103426218,8249,Unspecified,,,,,Antiobesity activity in lean normal BALB/c mouse assessed as change in average daily weight at 0.62 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
166,352975,3,3,,103426218,8249,Unspecified,,,,,Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.60 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
167,352976,3,3,,103426218,8249,Unspecified,,,,,Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.72 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
168,352977,3,3,,103426218,8249,Unspecified,,,,,Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.54 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
169,352978,3,3,,103426218,8249,Unspecified,,,,,Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.62 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
170,352979,3,3,,103426218,8249,Unspecified,,,,,Antidiabetic activity in lean normal BALB/c mouse assessed as effect on blood lactate level at 0.5 mmol/kg/day administered through diet for 7 days relative to time-matched control,Other,19422230.0,
171,374712,3,4,,103426218,8249,Unspecified,,,,,Metabolic stability in ob/ob mouse liver microsomes assessed as oxidative hydroxylation at 50 uM after 45 mins by HPLC-MS analysis,Other,19422230.0,
172,404304,3,10,,103426218,8249,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
173,434959,1,1,,85787916,8249,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
174,485281,1,1,,11112448,8249,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
175,485290,1,1,,11112448,8249,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
176,492961,1,1,,11112448,8249,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
177,496819,4,2,,103426218,8249,Unspecified,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
178,504327,1,1,,11112448,8249,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
179,504332,1,1,,11112448,8249,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
180,504749,1,3,,11112448,8249,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
181,504749,1,3,1.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
182,504749,1,3,2.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
183,504749,1,3,3.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
184,504749,1,3,4.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
185,504749,1,3,5.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
186,504749,1,3,6.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
187,504749,1,3,7.0,11112448,8249,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
188,504749,1,3,8.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
189,504749,1,3,9.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
190,504749,1,3,10.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
191,504749,1,3,11.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
192,504749,1,3,12.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
193,504749,1,3,13.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
194,504749,1,3,14.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
195,504749,1,3,15.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
196,504749,1,3,16.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
197,504749,1,3,17.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
198,504749,1,3,18.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
199,504749,1,3,19.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
200,504749,1,3,20.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
201,504749,1,3,21.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
202,504749,1,3,22.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
203,504749,1,3,23.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
204,504749,1,3,24.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
205,504749,1,3,25.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
206,504749,1,3,26.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
207,504749,1,3,27.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
208,504749,1,3,28.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
209,504749,1,3,29.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
210,504749,1,3,30.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
211,504749,1,3,31.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
212,504749,1,3,32.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
213,504749,1,3,33.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
214,504749,1,3,34.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
215,504749,1,3,35.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
216,504749,1,3,36.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
217,504749,1,3,37.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
218,504749,1,3,38.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
219,504749,1,3,39.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
220,504749,1,3,40.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
221,504749,1,3,41.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
222,504749,1,3,42.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
223,504749,1,3,43.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
224,504749,1,3,44.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
225,504749,1,3,45.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
226,504749,1,3,46.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
227,504749,1,3,47.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
228,504749,1,3,48.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
229,504749,1,3,49.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
230,504749,1,3,50.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
231,504749,1,3,51.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
232,504749,1,3,52.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
233,504749,1,3,53.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
234,504749,1,3,54.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
235,504749,1,3,55.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
236,504749,1,3,56.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
237,504749,1,3,57.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
238,504749,1,3,58.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
239,504749,1,3,59.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
240,504749,1,3,60.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
241,504749,1,3,61.0,11112448,8249,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
242,504832,1,1,,11112448,8249,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
243,504834,1,1,,11112448,8249,Inconclusive,,,8.0875,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
244,504847,1,1,,11112448,8249,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
245,504865,1,1,,11112448,8249,Inactive,118600387.0,7398.0,39.8107,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
246,540276,1,2,,11112448,8249,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
247,540276,1,2,,50100445,8249,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
248,588211,2,3,,103426218,8249,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
249,588212,2,3,,103426218,8249,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
250,588213,2,3,,103426218,8249,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
251,588579,1,1,,11112448,8249,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
252,602332,1,1,,11112448,8249,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
253,624030,1,2,,11112448,8249,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
254,624031,1,2,,11112448,8249,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
255,624032,1,2,,11112448,8249,Inconclusive,8393992.0,24660.0,13.7894,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
256,624044,1,2,,11112448,8249,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
257,624101,1,2,,85787916,8249,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
258,624136,1,1,,85787916,8249,Inactive,208342286.0,7157.0,,,mutant P53 Measured in Biochemical System Using Small Molecule MicroArray - 2077-01_Other_SinglePoint_HTS_Activity,Screening,,
259,624137,1,1,,85787916,8249,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
260,624138,1,1,,85787916,8249,Inactive,21618340.0,6774.0,,,SMM STAT-3 Measured in Biochemical System Using Small Molecule MicroArray - 2076-01_Other_SinglePoint_HTS_Activity_Set2,Screening,,
261,624139,1,1,,85787916,8249,Inactive,34577122.0,4790.0,,,NF-KappaB Measured in Biochemical System Using Small Molecule MicroArray - 2080-01_Other_SinglePoint_HTS_Activity,Screening,,
262,624141,1,1,,85787916,8249,Inactive,71774083.0,4609.0,,,SMM c-myc Measured in Biochemical System Using Small Molecule MicroArray - 2081-01_Other_SinglePoint_HTS_Activity,Screening,,
263,624151,1,1,,85787916,8249,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
264,624156,1,1,,85787916,8249,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
265,624170,1,1,,11112448,8249,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
266,624172,1,1,,11112448,8249,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
267,624173,1,3,,11112448,8249,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
268,624260,1,1,,85787916,8249,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
269,624296,1,1,,11112448,8249,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
270,624297,1,1,,11112448,8249,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
271,651548,1,1,,85787916,8249,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
272,651741,1,1,,124882390,8249,Inconclusive,20149576.0,4780.0,38.5708,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
273,679316,2,7,,103426218,8249,Unspecified,81872095.0,24904.0,15.6,Km,TP_TRANSPORTER: uptake in OCT1-expressing CHO cells,Confirmatory,12130709.0,
274,680364,3,6,,103426218,8249,Unspecified,313104181.0,6580.0,10.0,IC50,TP_TRANSPORTER: inhibition of Cimetidine uptake (Cimetidine: 1 uM) in Xenopus laevis oocytes,Confirmatory,12240953.0,
275,680369,3,6,,103426218,8249,Unspecified,313104182.0,6582.0,65.0,IC50,TP_TRANSPORTER: inhibition of Cimetidine uptake (Cimetidine: 1 uM) in Xenopus laevis oocytes,Confirmatory,12240953.0,
276,686977,2,1,,49698378,8249,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
277,699539,1,7,,103426218,8249,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
278,699540,1,7,,103426218,8249,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
279,699541,1,7,,103426218,8249,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
280,720636,1,1,,124882390,8249,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
281,743344,1,1,,174006812,8249,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
282,743345,1,1,,174006812,8249,Inactive,,,21.1177,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
283,743346,1,1,,174006812,8249,Inactive,,,14.9502,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
284,743347,1,1,,174006812,8249,Inactive,,,14.9502,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
285,771314,1,5,,103426218,8249,Unspecified,313104182.0,6582.0,,,Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake,Other,23984907.0,
286,771315,1,5,,103426218,8249,Unspecified,313104181.0,6580.0,,,Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake,Other,23984907.0,
287,771316,1,5,,103426218,8249,Unspecified,313104182.0,6582.0,,,Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis,Other,23984907.0,
288,771317,1,5,,103426218,8249,Unspecified,313104181.0,6580.0,,,Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis,Other,23984907.0,
289,1079931,1,1,,103426218,8249,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
290,1079932,1,1,,103426218,8249,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
291,1079933,1,1,,103426218,8249,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
292,1079934,1,1,,103426218,8249,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
293,1079935,1,1,,103426218,8249,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
294,1079936,1,1,,103426218,8249,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
295,1079937,1,1,,103426218,8249,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
296,1079938,1,1,,103426218,8249,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
297,1079939,1,1,,103426218,8249,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
298,1079940,1,1,,103426218,8249,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
299,1079941,1,1,,103426218,8249,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
300,1079942,1,1,,103426218,8249,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
301,1079943,1,1,,103426218,8249,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
302,1079944,1,1,,103426218,8249,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
303,1079945,1,1,,103426218,8249,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
304,1079946,1,1,,103426218,8249,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
305,1079947,1,1,,103426218,8249,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
306,1079948,1,1,,103426218,8249,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
307,1079949,1,1,,103426218,8249,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
308,1124003,1,2,,103426218,8249,Unspecified,,,,,"Hypoglycemic activity in alloxan-induced diabetic albino mouse assessed as decrease in blood glucose level at 1 mmol/kg, po administered 6 days after alloxan injection measured after 2 to 4 hrs by automated glucose oxidase method relative to control",Other,423216.0,
309,1124005,1,2,,103426218,8249,Unspecified,,,,,"Hypoglycemic activity in alloxan-induced diabetic albino mouse assessed as decrease in blood glucose level at 1 mmol/kg, po administered 6 days after alloxan injection measured after 1 to 3 hrs by automated glucose oxidase method relative to control",Other,423216.0,
310,1159580,2,1,,268735217,8249,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
311,1159607,2,1,,312596732,8249,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
312,1224824,1,1,,174006812,8249,Inactive,,,0.7427,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
313,1224825,1,1,,174006812,8249,Inactive,,,18.6548,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
314,1224857,2,1,,174006812,8249,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
315,1224859,2,1,,174006812,8249,Inactive,,,4.6859,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
316,1224863,1,1,,316919431,8249,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
317,1224923,1,1,,103426218,8249,Active,,,,,Summary of drugs withdrawn.,Other,,
318,1259252,1,1,,174006812,8249,Active,169655958.0,,11.7704,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
319,1259253,1,1,,174006812,8249,Active,169655958.0,,18.6548,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
320,1259255,1,1,,174006812,8249,Active,169655958.0,,16.6261,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
321,1259256,1,1,,174006812,8249,Inconclusive,169655958.0,,20.930999999999997,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
322,1259411,1,1,,363898450,8249,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
323,1259416,1,2,,340087819,8249,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
324,1259421,1,1,,340087819,8249,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
325,1259423,1,2,,354842222,8249,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
326,1259423,1,2,,354928183,8249,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
